Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorbipiprant + Balstilimab in MSS mCRC and other GI cancers
NCT05205330Phase 2Active, not recruiting
- Sponsor
- Rottapharm Biotech
- Start
- Nov 2021
- Primary completion
- Dec 2026
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorbipiprant in colorectal cancer (CRC), gastric cancer (GC), gastrointestinal cancer, sponsored by Rottapharm Biotech. Started Nov 2021; status: active, not recruiting.
02
Drugs
vorbipiprant
03
Conditions
colorectal cancer (CRC)gastric cancer (GC)gastrointestinal cancer
Beyond the preview
Go deeper on NCT05205330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05205330.